The tweet was deleted by the author.
But we saved everything 🙂.
Compass Therapeutics has announced the presentation of results from its Phase 2 3 COMPANION 002 trial targeting previously treated advanced biliary tract cancer.
The findings are being shared at the ESMO 2026 conference and have been published in the Journal of Clinical Oncology. This update provides new data on the companys investigational efforts in oncology, focusing on a patient population with limited treatment options.
View post on X Loading...